The current stock price likely implies Botox declines, but we think the franchise can maintain healthy growth as a result of expansion of the market and limited price competition. Firms Likely to Have ...
An enduring medical aesthetics franchise, led by wrinkle-fighter Botox, is one of the key reasons AbbVie is shelling out $63 billion for Allergan. That drug has again pulled off a sales jump, though a ...
Allergan has been more than willing to do whatever necessary to protect its secret process for making blockbuster Botox. After filing a trade theft investigation against a competitor, the drugmaker ...
Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results